Midland Wealth Advisors LLC decreased its place in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 3.2% within the second quarter, in keeping with the corporate in its most up-to-date disclosure with the Securities and Alternate Fee. The fund owned 16,954 shares of the corporate’s inventory after promoting 553 shares through the interval. Midland Wealth Advisors LLC’s holdings in Johnson & Johnson had been price $2,478,000 on the finish of the latest reporting interval.
Different institutional buyers have additionally lately purchased and bought shares of the corporate. Vestmark Advisory Options Inc. raised its holdings in shares of Johnson & Johnson by 12.7% through the 4th quarter. Vestmark Advisory Options Inc. now owns 19,587 shares of the corporate’s inventory valued at $3,070,000 after buying an extra 2,201 shares within the final quarter. Meridian Monetary Companions LLC purchased a brand new stake in Johnson & Johnson within the second quarter price $1,626,000. Summit Monetary Wealth Advisors LLC raised its holdings in Johnson & Johnson by 26.3% through the first quarter. Summit Monetary Wealth Advisors LLC now owns 5,392 shares of the corporate’s inventory valued at $853,000 after shopping for an extra 1,122 shares within the final quarter. Gilbert & Cook dinner Inc. lifted its place in shares of Johnson & Johnson by 3.3% within the fourth quarter. Gilbert & Cook dinner Inc. now owns 9,111 shares of the corporate’s inventory price $1,428,000 after shopping for an extra 288 shares over the last quarter. Lastly, Franklin Parlapiano Turner & Welch LLC boosted its stake in shares of Johnson & Johnson by 0.7% through the 1st quarter. Franklin Parlapiano Turner & Welch LLC now owns 47,186 shares of the corporate’s inventory price $7,464,000 after buying an extra 325 shares within the final quarter. Institutional buyers and hedge funds personal 69.55% of the corporate’s inventory.
Insider Shopping for and Promoting
In different Johnson & Johnson information, VP Robert J. Decker bought 5,635 shares of the corporate’s inventory in a transaction on Friday, August thirtieth. The inventory was bought at a mean worth of $165.06, for a complete worth of $930,113.10. Following the sale, the vice chairman now instantly owns 18,973 shares within the firm, valued at $3,131,683.38. The sale was disclosed in a doc filed with the Securities & Alternate Fee, which is accessible by this hyperlink. 0.16% of the inventory is owned by company insiders.
Johnson & Johnson Inventory Up 0.1 %
Shares of JNJ inventory opened at $167.27 on Thursday. The inventory has a market cap of $402.57 billion, a P/E ratio of 10.43, a price-to-earnings-growth ratio of two.73 and a beta of 0.52. The corporate has a debt-to-equity ratio of 0.44, a present ratio of 1.07 and a fast ratio of 0.85. The inventory has a fifty day transferring common worth of $156.82 and a 200 day transferring common worth of $153.70. Johnson & Johnson has a one yr low of $143.13 and a one yr excessive of $168.85.
Johnson & Johnson (NYSE:JNJ – Get Free Report) final issued its earnings outcomes on Wednesday, July seventeenth. The corporate reported $2.82 earnings per share for the quarter, beating the consensus estimate of $2.71 by $0.11. Johnson & Johnson had a internet margin of 46.34% and a return on fairness of 36.60%. The enterprise had income of $22.45 billion for the quarter, in comparison with analyst estimates of $22.33 billion. Throughout the identical interval within the earlier yr, the enterprise earned $2.80 EPS. The agency’s income was up 4.3% on a year-over-year foundation. Analysts predict that Johnson & Johnson will put up 10.02 earnings per share for the present yr.
Johnson & Johnson Dividend Announcement
The enterprise additionally lately introduced a quarterly dividend, which can be paid on Tuesday, September tenth. Stockholders of file on Tuesday, August twenty seventh can be issued a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, August twenty seventh. This represents a $4.96 dividend on an annualized foundation and a dividend yield of two.97%. Johnson & Johnson’s payout ratio is presently 30.92%.
Analyst Upgrades and Downgrades
Numerous brokerages lately weighed in on JNJ. Morgan Stanley boosted their goal worth on Johnson & Johnson from $167.00 to $169.00 and gave the inventory an “equal weight” score in a report on Thursday, July 18th. Daiwa Capital Markets lowered shares of Johnson & Johnson from an “outperform” score to a “impartial” score and dropped their worth goal for the corporate from $160.00 to $150.00 in a analysis report on Tuesday, July twenty third. Royal Financial institution of Canada reaffirmed an “outperform” score and set a $175.00 worth goal on shares of Johnson & Johnson in a report on Tuesday, July thirtieth. The Goldman Sachs Group dropped their goal worth on shares of Johnson & Johnson from $160.00 to $155.00 and set a “impartial” score on the inventory in a report on Friday, July nineteenth. Lastly, Sanford C. Bernstein upped their worth goal on shares of Johnson & Johnson from $161.00 to $171.00 in a report on Thursday, July 18th. Seven analysts have rated the inventory with a maintain score, six have assigned a purchase score and one has issued a robust purchase score to the corporate. Primarily based on information from MarketBeat.com, the inventory has a mean score of “Reasonable Purchase” and a mean worth goal of $173.21.
Get Our Newest Analysis Report on Johnson & Johnson
About Johnson & Johnson
Johnson & Johnson, along with its subsidiaries, researches, develops, manufactures, and sells varied merchandise within the healthcare discipline worldwide. The corporate’s Modern Medication phase affords merchandise for varied therapeutic areas, corresponding to immunology, together with rheumatoid arthritis, psoriatic arthritis, inflammatory bowel illness, and psoriasis; infectious ailments comprising HIV/AIDS; neuroscience, consisting of temper issues, neurodegenerative issues, and schizophrenia; oncology, corresponding to prostate most cancers, hematologic malignancies, lung most cancers, and bladder most cancers; cardiovascular and metabolism, together with thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension by retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
Learn Extra
Need to see what different hedge funds are holding JNJ? Go to HoldingsChannel.com to get the most recent 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Obtain Information & Scores for Johnson & Johnson Each day – Enter your e-mail deal with under to obtain a concise every day abstract of the most recent information and analysts’ rankings for Johnson & Johnson and associated corporations with MarketBeat.com’s FREE every day e-mail publication.
